Allergy Therapeutics plc Company Profile (LON:AGY)

About Allergy Therapeutics plc (LON:AGY)

Allergy Therapeutics plc logoAllergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company's segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World. The Company provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with focus on allergy vaccination, which is also known as specific immunotherapy or desensitization therapy. The Company's products include Pollinex Trees, Pollinex Grasses+Rye, Skin Prick Testing and diagnostic products. Its vaccines trade under various brand names, such as Pollinex Quattro, Polligoid and TA Graser Top. It uses specialized systems to process the Tyrosine to form a suspension microcrystalline tyrosine (MCT) that is combined with some of its subcutaneous injected therapies.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: £192.13 million
  • Outstanding Shares: 593,443,000
Average Prices:
  • 50 Day Moving Avg: GBX 29.75
  • 200 Day Moving Avg: GBX 27.73
  • 52 Week Range: GBX 17.25 - GBX 33
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 54.310
Sales & Book Value:
  • Annual Revenue: £59.98 million
  • Price / Sales: 3.20
  • Book Value: GBX 0.07 per share
  • Price / Book: 4.98
Profitability:
  • EBIDTA: ($4,440,000.00)
  • Net Margins: 16.92%
  • Return on Equity: 39.67%
  • Return on Assets: 22.45%
Misc:
  • Average Volume: 143,377 shs.
 

Frequently Asked Questions for Allergy Therapeutics plc (LON:AGY)

What is Allergy Therapeutics plc's stock symbol?

Allergy Therapeutics plc trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

When will Allergy Therapeutics plc make its next earnings announcement?

Allergy Therapeutics plc is scheduled to release their next quarterly earnings announcement on Monday, September, 25th 2017. View Earnings Estimates for Allergy Therapeutics plc.

Where is Allergy Therapeutics plc's stock going? Where will Allergy Therapeutics plc's stock price be in 2017?

4 brokerages have issued twelve-month price objectives for Allergy Therapeutics plc's shares. Their forecasts range from GBX 45 to GBX 60. On average, they expect Allergy Therapeutics plc's stock price to reach GBX 51 in the next year. View Analyst Ratings for Allergy Therapeutics plc.

Who are some of Allergy Therapeutics plc's key competitors?

Who are Allergy Therapeutics plc's key executives?

Allergy Therapeutics plc's management team includes the folowing people:

  • Manuel Llobet, Chief Executive Officer, Executive Director
  • Nicolas Alexander Ulrich Wykeman, Finance Director
  • Peter Sinclair Jensen, Non-Executive Chairman of the Board
  • Jeff Barton, Non-Executive Director
  • Tunde Otulana, Non-Executive Director
  • Stephen Rushworth Smith, Senior Non-Executive Independent Director

How do I buy Allergy Therapeutics plc stock?

Shares of Allergy Therapeutics plc and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics plc's stock price today?

One share of Allergy Therapeutics plc stock can currently be purchased for approximately GBX 32.38.


MarketBeat Community Rating for Allergy Therapeutics plc (LON AGY)
Community Ranking:  4.1 out of 5 (star star star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  40 (Vote Underperform)
Total Votes:  235
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allergy Therapeutics plc (LON:AGY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: GBX 51

Analysts' Ratings History for Allergy Therapeutics plc (LON:AGY)
Show:
DateFirmActionRatingPrice TargetDetails
9/18/2017Panmure GordonReiterated RatingBuyView Rating Details
8/24/2017FinnCapReiterated RatingBuyGBX 46View Rating Details
7/18/2017Numis Securities LtdReiterated RatingBuyGBX 45View Rating Details
4/4/2017Stifel NicolausReiterated RatingBuyGBX 60View Rating Details
(Data available from 9/19/2015 forward)

Earnings

Earnings History for Allergy Therapeutics plc (LON:AGY)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Allergy Therapeutics plc (LON:AGY)
Current Year EPS Consensus Estimate: $-0.580 EPS

Dividends

Dividend History for Allergy Therapeutics plc (LON:AGY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Allergy Therapeutics plc (LON:AGY)
Insider Trades by Quarter for Allergy Therapeutics plc (LON:AGY)
Insider Trades by Quarter for Allergy Therapeutics plc (LON:AGY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/29/2016Peter JensenInsiderBuy30,000GBX 19£5,700
9/27/2016Nicolas WykemanInsiderBuy150,000GBX 18£27,000
7/27/2015Llobet ,ManuelInsiderBuy50,000GBX 24£12,000
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Allergy Therapeutics plc (LON:AGY)
Latest Headlines for Allergy Therapeutics plc (LON:AGY)
Source:
DateHeadline
americanbankingnews.com logoAllergy Therapeutics plc (AGY) Stock Rating Reaffirmed by FinnCap
www.americanbankingnews.com - August 28 at 5:02 PM
finance.yahoo.com logo[$$] Small-cap focus: UK's booming biotech groups
finance.yahoo.com - June 23 at 3:56 PM
finance.yahoo.com logoAllergy Therapeutics Plc breached its 50 day moving average in a Bullish Manner : AGY-GB : May 18, 2017
finance.yahoo.com - May 18 at 12:20 PM
finance.yahoo.com logoAllergy Therapeutics Plc :AGY-GB: Earnings Analysis: For the six months ended December 31, 2016 : May 12, 2017
finance.yahoo.com - May 12 at 8:59 PM
finance.yahoo.com logoAllergy Therapeutics Plc – Value Analysis (LONDON:AGY) : May 8, 2017
finance.yahoo.com - May 8 at 8:23 PM
finance.yahoo.com logoAllergy Therapeutics Plc breached its 50 day moving average in a Bearish Manner : AGY-GB : May 5, 2017
finance.yahoo.com - May 5 at 3:25 PM
americanbankingnews.com logoAllergy Therapeutics plc (AGY) Given Buy Rating at Panmure Gordon
www.americanbankingnews.com - April 20 at 6:59 PM
americanbankingnews.com logoAllergy Therapeutics plc (AGY) Earns "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 8 at 6:08 PM
americanbankingnews.com logoNumis Securities Ltd Increases Allergy Therapeutics plc (AGY) Price Target to GBX 45
www.americanbankingnews.com - April 4 at 1:16 PM
americanbankingnews.com logoAllergy Therapeutics plc (AGY) Receives Buy Rating from FinnCap
www.americanbankingnews.com - March 29 at 7:45 PM
americanbankingnews.com logoFinnCap Reiterates "Buy" Rating for Allergy Therapeutics plc (AGY)
www.americanbankingnews.com - March 22 at 5:22 AM
biz.yahoo.com logoHalf Year 2017 Allergy Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - March 9 at 3:28 PM
finance.yahoo.com logoAllergy Therapeutics: Positive Efficacy and Safety Data Shown in Peanut Allergy Vaccine
finance.yahoo.com - February 1 at 3:27 PM
finanznachrichten.de logoDGAP-News: Bencard Allergie GmbH: Update zur ... - FinanzNachrichten.de
www.finanznachrichten.de - January 19 at 3:42 PM
bloomberg.com logoSecretive Biotech Unicorn Moderna Unveils Pipeline, Financials - Bloomberg
www.bloomberg.com - January 10 at 1:41 AM
globenewswire.com logoUltragenyx and Kyowa Kirin International Announce Marketing Authorization Application for KRN23 Filed and Accepted ... - GlobeNewswire (press release)
globenewswire.com - January 5 at 8:32 PM
uk.finance.yahoo.com logoDo today’s results make this company a better buy than Shire plc?
uk.finance.yahoo.com - September 26 at 9:32 AM
biz.yahoo.com logoFull Year 2016 Allergy Therapeutics PLC Earnings Release - Before Market Open
biz.yahoo.com - September 26 at 9:32 AM

Social

Social activity is not available for this stock.

Chart

Allergy Therapeutics plc (AGY) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by MarketBeat.com Staff